Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2026-10-05

Roivant Sciences Ltd. (ROIV)

CEO Matthew Gline was paid $163,293,744 in fiscal year 2024, ↑ up 22020.9% from fiscal year 2023, the 99th percentile of its disclosed peer group (SEC filing 0001140361-25-027846 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$251,858,764
Mayukh Sukhatme total, FY2024
President and Chief Investment Officer — highest-paid officer; CEO Matthew Gline: $163,293,744
99th
CEO (Matthew Gline) pay percentile vs peers
518:1
CEO-to-median pay ratio
60.91%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Matthew Gline (Chief Executive Officer), FY2024 total compensation $163,293,744 (base salary $725,000) [exec_comp, SEC accession 0001140361-25-027846, filed 2025-07-29]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Mayukh Sukhatme$550,000$81,069,750$170,217,983———$21,032$251,858,764
President and Chief Investment Officer
Matthew Gline725,0004,978,875157,577,851———12,018163,293,744
Chief Executive Officer
Eric Venker600,2086,038,1752,203,2002,933,103——32,73611,807,422
President and Immunovant CEO
Rakhi Kumar370,1561,650,328412,3821,862,828——398,2444,693,938
Former Chief Accounting Officer
Richard Pulik437,7501,113,674410,0612,163,910——1,7554,127,151
Chief Financial Officer
Jennifer Humes41,897281,4501,231,437826,878——1,2932,382,956
Chief Accounting Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Mayukh Sukhatme$251,858,764$574,560$48,925,582↑ +251,284,204
Matthew Gline163,293,744738,18948,978,825↑ +162,555,555
Eric Venker11,807,422632,42048,487,966↑ +11,175,002
Rakhi Kumar4,693,9384,331,159—↑ +362,779
Richard Pulik4,127,1515,149,434—↓ −1,022,283
Jennifer Humes2,382,956———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Roivant Sciences Ltd.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ROIV reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

Get the Roivant Sciences Ltd. Peer Teardown Report

$251,858,764 Mayukh Sukhatme total, FY2024

$199

The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.

Data as of October 5, 2026 · Source: 0001140361-25-027846 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Reports for ROIV

Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:

Executive Compensation ReportThe free page is the headline figures. The report is every award, peer and vote combined into one document you can hand to a committee.$1,500 →Reverse Peer AnalysisThe free page is the one line. The analysis reads every company that names this one in its own peer group.$299 →Peer Teardown ReportThe free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.$199 →
ROIVon Velarion Intel, free → The platform reading of this company, beside the same data as a subscription.

Order ROIV

Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

How we handle your data → Privacy

Companies that benchmark against ROIV
4 companies name ROIV as a compensation peer

Each company listed discloses ROIV in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ROIV in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Get the Roivant Sciences Ltd. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
Daniel GoldIndependent Director$484,410
Ilan OrenIndependent Director$521,548
James C. MomtazeeIndependent Director$473,844
Keith ManchesterIndependent Director$476,660
Meghan FitzGeraldIndependent Director$482,910
Melissa EpperlyIndependent Director$489,410
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Richard PulikCFO2025-12-23D146,731$22$3,285,307CommonForm 4 ↗
Richard PulikCFO2025-12-23A260,00041,001,000CommonForm 4 ↗
Frank TortiPresident and Vant Chair2025-12-23A175,380223,937,281CommonForm 4 ↗
Frank TortiPresident and Vant Chair2025-12-24D64,891221,458,101CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2025-12-24D75,000231,689,750CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2025-12-24A117,8484453,715CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2025-12-24D117,84800Derivative, Class A CommonForm 4 ↗
Frank TortiPresident and Vant Chair2025-12-24D110,48900CommonForm 4 ↗
Mayukh SukhatmeDirector2025-12-29D748,35800Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2025-12-29D311,873226,780,119CommonForm 4 ↗
Mayukh SukhatmeDirector2025-12-29D436,485229,489,184CommonForm 4 ↗
Mayukh SukhatmeDirector2025-12-29A748,358139,489,179CommonForm 4 ↗
Mayukh SukhatmeDirector2025-12-31D1,430,8822231,064,448CommonForm 4 ↗
Mayukh SukhatmeDirector2025-12-31D1,018,9952222,122,381CommonForm 4 ↗
Mayukh SukhatmeDirector2025-12-31D2,449,87700Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2025-12-31A2,449,8771331,064,440CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-01-12D200,000224,384,000CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-01-12A200,0004770,000CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-01-12D200,00000Derivative, Class A CommonForm 4 ↗
Epperly Melissa B,Director2026-01-20D54231,241CommonForm 4 ↗
Ilan OrenDirector2026-01-20D124232,850CommonForm 4 ↗
James C. MomtazeeDirector2026-01-20D122232,804CommonForm 4 ↗
Epperly Melissa B,Director2026-01-20A81500CommonForm 4 ↗
Ilan OrenDirector2026-01-20A1,16400CommonForm 4 ↗
James C. MomtazeeDirector2026-01-20A60900CommonForm 4 ↗
Mayukh SukhatmeDirector2026-02-09D651,55800Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2026-02-09D312,117268,261,737CommonForm 4 ↗
Mayukh SukhatmeDirector2026-02-09A651,558138,261,755CommonForm 4 ↗
Mayukh SukhatmeDirector2026-02-09D339,441268,985,003CommonForm 4 ↗
QVT Financial LP—2026-02-11D425,0002711,334,750Common, indirectForm 4 ↗
Daniel GoldDirector2026-02-11D425,0002711,334,750Common, indirectForm 4 ↗
Keith ManchesterDirector2026-02-11D425,0002711,334,750Common, indirectForm 4 ↗
Daniel GoldDirector2026-02-12D275,000277,359,000Common, indirectForm 4 ↗
Daniel GoldDirector2026-02-12D150,000274,008,000Common, indirectForm 4 ↗
Keith ManchesterDirector2026-02-12D275,000277,359,000Common, indirectForm 4 ↗
Keith ManchesterDirector2026-02-12D150,000274,008,000Common, indirectForm 4 ↗
QVT Financial LP—2026-02-12D275,000277,359,000Common, indirectForm 4 ↗
QVT Financial LP—2026-02-12D150,000274,008,000Common, indirectForm 4 ↗
QVT Financial LP—2026-02-13D225,000275,962,500Common, indirectForm 4 ↗
Daniel GoldDirector2026-02-13D150,784263,994,268Common, indirectForm 4 ↗
Keith ManchesterDirector2026-02-13D225,000275,962,500Common, indirectForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-02-13D200,000265,298,000CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-02-13D200,00000Derivative, Class A CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-02-13A200,0004770,000CommonForm 4 ↗
QVT Financial LP—2026-02-13D150,784263,994,268Common, indirectForm 4 ↗
Daniel GoldDirector2026-02-13D225,000275,962,500Common, indirectForm 4 ↗
Keith ManchesterDirector2026-02-13D150,784263,994,268Common, indirectForm 4 ↗
Frank TortiPresident and Vant Chair2026-02-19D1,400,00000Derivative, Class A CommonForm 4 ↗
Frank TortiPresident and Vant Chair2026-02-19D1,400,0002738,388,000CommonForm 4 ↗
Frank TortiPresident and Vant Chair2026-02-19A1,400,00045,390,000CommonForm 4 ↗
Frank TortiPresident and Vant Chair2026-02-20D1,012,61000Derivative, Class A CommonForm 4 ↗
Frank TortiPresident and Vant Chair2026-02-20D1,012,6102727,492,362CommonForm 4 ↗
Frank TortiPresident and Vant Chair2026-02-20A1,012,61043,898,549CommonForm 4 ↗
Richard PulikCFO2026-02-20D1,0002727,150CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-02-20D7,05127191,435CommonForm 4 ↗
Frank TortiPresident and Vant Chair2026-02-23A587,39042,261,452CommonForm 4 ↗
Frank TortiPresident and Vant Chair2026-02-23D587,39000Derivative, Class A CommonForm 4 ↗
Frank TortiPresident and Vant Chair2026-02-23D587,3902816,159,099CommonForm 4 ↗
Epperly Melissa B,Director2026-03-16D41,861291,200,573CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-03-17D200,00000Derivative, Class A CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-03-17D200,000285,648,000CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-03-17A200,0004770,000CommonForm 4 ↗
Jennifer HumesChief Accounting Officer2026-03-20D14,52628402,370CommonForm 4 ↗
Richard PulikCFO2026-03-20D1,5462842,824CommonForm 4 ↗
Meghan FitzGeraldDirector2026-03-26D70,000271,921,500CommonForm 4 ↗
Meghan FitzGeraldDirector2026-03-26D70,00000Derivative, Class A CommonForm 4 ↗
Meghan FitzGeraldDirector2026-03-26A70,0009616,000CommonForm 4 ↗
Matthew GlineDirector2026-03-30D2,178,1501225,048,725Derivative, Class A CommonForm 4 ↗
Matthew GlineDirector2026-03-30D53,826261,421,545CommonForm 4 ↗
Mayukh SukhatmeDirector2026-03-30D29,80926787,256CommonForm 4 ↗
Matthew GlineDirector2026-03-30A97,319——CommonForm 4 ↗
Mayukh SukhatmeDirector2026-03-30D1,306,8891215,029,224Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2026-03-30A58,391——CommonForm 4 ↗
Mayukh SukhatmeDirector2026-03-31D187,512285,194,082CommonForm 4 ↗
Matthew GlineDirector2026-03-31D304,684288,439,747CommonForm 4 ↗
Frank TortiPresident and Vant Chair2026-03-31D160,035284,432,970CommonForm 4 ↗
Jennifer HumesChief Accounting Officer2026-04-08D13,53828384,073CommonForm 4 ↗
Matthew GlineDirector2026-04-16D289,774298,449,810CommonForm 4 ↗
Ilan OrenDirector2026-04-17D95302,834CommonForm 4 ↗
James C. MomtazeeDirector2026-04-17A46900CommonForm 4 ↗
James C. MomtazeeDirector2026-04-17D94302,804CommonForm 4 ↗
Ilan OrenDirector2026-04-17A89600CommonForm 4 ↗
Epperly Melissa B,Director2026-04-17A67000CommonForm 4 ↗
Richard PulikCFO2026-04-20A84,02600Derivative, Class A CommonForm 4 ↗
Jennifer HumesChief Accounting Officer2026-04-20A27,15700Derivative, Class A CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-04-20D200,00000Derivative, Class A CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-04-20D200,000305,918,000CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-04-20A200,0004770,000CommonForm 4 ↗
Jennifer HumesChief Accounting Officer2026-04-20A29,17300CommonForm 4 ↗
Richard PulikCFO2026-04-20A60,64400CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-05-20D34,483321,117,594CommonForm 4 ↗
Richard PulikCFO2026-05-20D18,96232614,558CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-05-22D200,00000Derivative, Class A CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-05-22D200,000306,054,000CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-05-22A200,0004770,000CommonForm 4 ↗
Richard PulikCFO2026-06-20D2,1293166,914CommonForm 4 ↗
Jennifer HumesChief Accounting Officer2026-06-20D3,58231112,582CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-06-24D46,234341,549,301CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-06-24D200,00000Derivative, Class A CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-06-24D153,766335,081,966CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-06-24A200,0004770,000CommonForm 4 ↗
Mayukh SukhatmeDirector2026-06-25A500,00041,925,000CommonForm 4 ↗
Mayukh SukhatmeDirector2026-06-25D500,00000Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2026-06-25D500,0003417,065,000CommonForm 4 ↗
Mayukh SukhatmeDirector2026-06-26D500,00000Derivative, Class A CommonForm 4 ↗
Daniel GoldDirector2026-06-26D300,7833410,202,559Common, indirectForm 4 ↗
QVT Financial LP—2026-06-26D325,0003411,072,750Common, indirectForm 4 ↗
QVT Financial LP—2026-06-26D300,7833410,202,559Common, indirectForm 4 ↗
Keith ManchesterDirector2026-06-26D300,7833410,202,559Common, indirectForm 4 ↗
Mayukh SukhatmeDirector2026-06-26D500,0003417,040,000CommonForm 4 ↗
Mayukh SukhatmeDirector2026-06-26A500,00041,925,000CommonForm 4 ↗
Daniel GoldDirector2026-06-26D325,0003411,072,750Common, indirectForm 4 ↗
Keith ManchesterDirector2026-06-26D325,0003411,072,750Common, indirectForm 4 ↗
QVT Financial LP—2026-06-29D600,0003520,754,000Common, indirectForm 4 ↗
Keith ManchesterDirector2026-06-29D200,000346,888,000Common, indirectForm 4 ↗
Epperly Melissa B,Director2026-06-29D17,75000Derivative, Class A CommonForm 4 ↗
Epperly Melissa B,Director2026-06-29D2,7483595,383CommonForm 4 ↗
Epperly Melissa B,Director2026-06-29D15,00234514,869CommonForm 4 ↗
Daniel GoldDirector2026-06-29D600,0003520,754,000Common, indirectForm 4 ↗
Daniel GoldDirector2026-06-29D200,000346,888,000Common, indirectForm 4 ↗
QVT Financial LP—2026-06-29D200,000346,888,000Common, indirectForm 4 ↗
Keith ManchesterDirector2026-06-29D600,0003520,754,000Common, indirectForm 4 ↗
Epperly Melissa B,Director2026-06-29A17,750479,165CommonForm 4 ↗
QVT Financial LP—2026-06-30D12,38035436,766Common, indirectForm 4 ↗
Meghan FitzGeraldDirector2026-06-30A10,000988,000CommonForm 4 ↗
Matthew GlineDirector2026-06-30D76,171352,695,692CommonForm 4 ↗
Keith ManchesterDirector2026-06-30D12,38035436,766Common, indirectForm 4 ↗
Mayukh SukhatmeDirector2026-06-30D46,878351,659,012CommonForm 4 ↗
Keith ManchesterDirector2026-06-30D200,000357,090,000CommonForm 4 ↗
Frank TortiPresident and Vant Chair2026-06-30D40,310351,426,571CommonForm 4 ↗
Meghan FitzGeraldDirector2026-06-30D10,00000Derivative, Class A CommonForm 4 ↗
Meghan FitzGeraldDirector2026-06-30D10,00035349,000CommonForm 4 ↗
Daniel GoldDirector2026-06-30D12,38035436,766Common, indirectForm 4 ↗
Ilan OrenDirector2026-07-17A77500CommonForm 4 ↗
James C. MomtazeeDirector2026-07-17A40500CommonForm 4 ↗
Epperly Melissa B,Director2026-07-17A54300CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-07-27A200,0004770,000CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-07-27D200,000356,990,000CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-07-27D200,00000Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-14D243,17700Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-14A243,1774936,231CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-14D243,177368,810,303CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-17D284,70700Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-17D284,7073610,320,629CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-17A284,70741,096,122CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-18D31,801371,182,361CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-18D136,94200Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-18D105,141373,847,109CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-18A31,8014122,434CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-18A105,1414404,793CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-19A172,8994665,661CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-19D172,89900Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-19D172,899376,426,656CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-08-20D13,90937512,408CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-20D17,51900Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-20D17,51937653,459CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-20A17,519467,448CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-21D144,756365,280,699CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-21D144,75600Derivative, Class A CommonForm 4 ↗
Mayukh SukhatmeDirector2026-08-21A144,7564557,311CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-08-28D200,00000Derivative, Class A CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-08-28D166,182365,921,065CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-08-28A200,0004770,000CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-08-28D33,818361,232,328CommonForm 4 ↗
Meghan FitzGeraldDirector2026-09-08D20,00000Derivative, Class A CommonForm 4 ↗
Meghan FitzGeraldDirector2026-09-08A20,0009176,000CommonForm 4 ↗
Meghan FitzGeraldDirector2026-09-08D20,00040798,000CommonForm 4 ↗
Epperly Melissa B,Director2026-09-10D2,1794189,208CommonForm 4 ↗
James C. MomtazeeDirector2026-09-10D2,90541118,931CommonForm 4 ↗
Meghan FitzGeraldDirector2026-09-10D1,7434171,358CommonForm 4 ↗
Daniel GoldDirector2026-09-10D5,13341210,145CommonForm 4 ↗
Ilan OrenDirector2026-09-10D2,3784197,355CommonForm 4 ↗
Epperly Melissa B,Director2026-09-15D4,33840172,002CommonForm 4 ↗
Meghan FitzGeraldDirector2026-09-15D4004016,180CommonForm 4 ↗
Epperly Melissa B,Director2026-09-15D6004024,228CommonForm 4 ↗
Meghan FitzGeraldDirector2026-09-15D4,71240186,972CommonForm 4 ↗
Epperly Melissa B,Director2026-09-16A5,05400CommonForm 4 ↗
James C. MomtazeeDirector2026-09-16A10,53100Derivative, Class A CommonForm 4 ↗
James C. MomtazeeDirector2026-09-16A5,05400CommonForm 4 ↗
Ilan OrenDirector2026-09-16A5,05400CommonForm 4 ↗
Daniel GoldDirector2026-09-16A10,53100Derivative, Class A CommonForm 4 ↗
Daniel GoldDirector2026-09-16A5,05400CommonForm 4 ↗
Keith ManchesterDirector2026-09-16A10,53100Derivative, Class A CommonForm 4 ↗
Keith ManchesterDirector2026-09-16A5,05400CommonForm 4 ↗
Epperly Melissa B,Director2026-09-16A10,53100Derivative, Class A CommonForm 4 ↗
Ilan OrenDirector2026-09-16A10,53100Derivative, Class A CommonForm 4 ↗
Meghan FitzGeraldDirector2026-09-16A10,53100Derivative, Class A CommonForm 4 ↗
Meghan FitzGeraldDirector2026-09-16A5,05400CommonForm 4 ↗
Richard PulikCFO2026-09-20D2,1294084,670CommonForm 4 ↗
Jennifer HumesChief Accounting Officer2026-09-20D3,88040154,308CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-09-30D200,00000Derivative, Class A CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-09-30D200,000377,324,000CommonForm 4 ↗
Eric VenkerPresident & Immunovant CEO2026-09-30A200,0004770,000CommonForm 4 ↗
Mayukh SukhatmeDirector2026-09-30D46,879371,714,365CommonForm 4 ↗
Matthew GlineDirector2026-09-30D76,171372,785,573CommonForm 4 ↗
Frank TortiPresident and Vant Chair2026-09-30A40,309371,474,100CommonForm 4 ↗
Epperly Melissa B,Director2026-10-01D17,75000Derivative, Class A CommonForm 4 ↗
Epperly Melissa B,Director2026-10-01D9003732,913CommonForm 4 ↗
Epperly Melissa B,Director2026-10-01D16,85036607,948CommonForm 4 ↗
Epperly Melissa B,Director2026-10-01A17,750479,165CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Mayukh SukhatmeRSU2024-07-26——1,836,547—$19,834,708
Jennifer HumesRSU2025-03-20——112,255—1,231,437
Rakhi KumarOPTION2024-04-22——230,548—1,862,828
Richard PulikOPTION2024-04-22——302,594—2,163,910
Jennifer HumesOPTION2025-03-20——115,108—826,878
Eric VenkerOPTION2024-07-26——409,000—2,933,103
Rakhi KumarRSU2024-04-22——38,685—412,382
Richard PulikRSU2024-04-22——38,685—410,061
Matthew GlineRSU2024-07-26——2,754,821—29,752,067
Eric VenkerRSU2024-07-26——204,000—2,203,200
Matthew GlinePSU2024-07-262,125,595——14,450,000127,825,784
Mayukh SukhatmePSU2024-07-262,500,700——17,000,000150,383,275
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Mayukh Sukhatme$19,834,708$150,383,275$088.3%
Jennifer Humes1,231,4370826,8780.0%
Rakhi Kumar412,38201,862,8280.0%
Richard Pulik410,06102,163,9100.0%
Eric Venker2,203,20002,933,1030.0%
Matthew Gline29,752,067127,825,784081.1%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Rakhi KumarOption230,54810.6—
Mayukh SukhatmeOption82,06510—
Eric VenkerOption58,61610—
Matthew GlineOption46,89410—
Eric VenkerOption23,44710—
Richard PulikOption39,1776—
Mayukh SukhatmeRSU1,836,547—18,530,759
Jennifer HumesOption115,10810.97—
Eric VenkerOption4,475,0293.85—
Matthew GlinePSU2,125,595—21,447,254
Eric VenkerRSU39,584—399,403
Matthew GlineOption4,475,0293.85—
Rakhi KumarRSU3,750—37,838
Matthew GlineOption58,61610—
Matthew GlineRSU2,754,821—27,796,144
Mayukh SukhatmePSU2,500,700—25,232,063
Richard PulikRSU27,502—277,495
Eric VenkerOption409,00010.8—
Rakhi KumarOption3,56610—
Richard PulikOption302,59410.6—
Rakhi KumarOption149,1718.8—
Eric VenkerRSU204,000—2,058,360
Matthew GlineRSU39,584—399,403
Rakhi KumarOption270,8333.85—
Richard PulikRSU38,685—390,332
Richard PulikRSU33,352—336,522
Richard PulikOption270,8333.85—
Rakhi KumarRSU38,685—390,332
Rakhi KumarRSU33,352—336,522
Jennifer HumesRSU112,255—1,132,653
Richard PulikOption199,7378.8—
Mayukh SukhatmeOption1,097,32510.96—
Mayukh SukhatmeOption4,475,0293.85—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program is designed to advance those objectives through a pay for performance philosophy and the alignment of the long-term interests of our NEOs with those of the Company's shareholders.

CEO STI target (% of salary)100%
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-09-10316,651,402203,244,18464,550,27660.91%Passed
20242024-09-10540,184,95164,461,892587,93089.34%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20252025-09-1060.91%a
20242024-09-1089.34%b

a. Approved under the standard stated in the filing — “Abstentions, where applicable, are not considered to be votes cast and therefore will have no effect on the outcome of the vote for any such proposals as long as a quorum exists.”.

b. Approved under the standard stated in the filing — “Abstentions, where applicable, are not considered to be votes cast and therefore will have no effect on the outcome of the vote for any such proposals as long as a quorum exists proxy materials, or contact your broker, bank or other agent to request a proxy form.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)518 : 1
CEO total compensation$163,293,744
Median employee compensation$315,444
08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Ilan OrenIndependent · Compensation · Nominating/Governance (Chair)$107,137$199,989$214,421$0$0$521,548
Melissa EpperlyIndependent · Audit (Chair)75,000199,989214,4210—489,410
Daniel GoldIndependent · Compensation (Chair)70,000199,989214,4210—484,410
Meghan FitzGeraldIndependent · Audit · Nominating/Governance68,500199,989214,4210—482,910
Keith ManchesterIndependent · Audit62,250199,989214,4210—476,660
James C. MomtazeeIndependent · Nominating/Governance59,434199,989214,4210—473,844
Matthew GlineEmployee director000—00
Mayukh SukhatmeEmployee director000—00
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$400,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)25,000 / 20,000 / 12,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$442,321
Equity awards (grant-date value)$1,199,934
All other compensation$0
Total cost of the board$1,642,255

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Roivant Sciences Ltd. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Roivant Sciences Ltd..

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Roivant Sciences Ltd.2024Matthew Gline$725,000$157,577,851——$163,293,744
2Exelixis, Inc.2025Michael Morrissey1,306,04030,539,55201,382,59133,239,183
3Incyte Corporation2025William Meury647,26027,509,6572,573,9981,300,00032,085,952
4Halozyme Therapeutics, Inc.2025Helen Torley1,000,00019,350,1451,650,0141,147,50023,166,223
5Jazz Pharmaceuticals, Inc.2025Renee Gala1,003,26916,138,43301,980,00019,151,558
6United Therapeutics Corporation2025Martine Rothblatt1,545,0056,067,9906,075,8044,281,87518,038,972
7BridgeBio Pharma, Inc.2025Neil Kumar1,044,00010,606,2751,874,992014,944,585
8Revolution Medicines, Inc.2025Mark Goldsmith812,5003,968,0768,995,114889,70014,672,390
9Vaxcyte, Inc.2025Grant Pickering800,0004,300,1598,714,048630,00014,458,937
10Blueprint Medicines Corporation2024Kathryn Haviland821,3637,472,4804,315,144854,21713,477,004
11Neurocrine Biosciences Inc.2025Kyle Gano920,0005,750,0235,750,006013,448,935
12Ionis Pharmaceuticals, Inc.2025Brett Monia1,051,7768,444,8381,438,105013,350,777
13Cerevel Therapeutics Holdings, Inc.2022N. Anthony Coles642,735010,085,985496,70611,225,426
14Karuna Therapeutics, Inc.2022Steven Paul700,00009,905,953609,00011,224,103
15Apellis Pharmaceuticals, Inc.2024Cedric Francois793,1934,779,8324,787,768010,957,451
16Axsome Therapeutics, Inc.2025Herriot Tabuteau835,0005,533,5542,833,237876,75010,283,492
17Intra-Cellular Therapies, Inc.2023Sharon Mates891,6537,749,9840010,086,413
18Amicus Therapeutics, Inc.2024Bradley Campbell767,3084,990,3652,105,62708,526,943
19ACADIA Pharmaceuticals Inc.2025Catherine Owen Adams930,0003,240,5583,234,797818,5598,256,518
20Sarepta Therapeutics, Inc.2025Douglas Ingram1,171,4256,000,0050649,0007,840,666
21CRISPR Therapeutics, Inc.2025Samarth Kulkarni768,6223,474,9002,768,862659,0937,678,477
22Arcutis Biotherapeutics, Inc.2025Todd Franklin Watanabe713,3332,067,1903,848,958579,5847,223,065
23ImmunoGen, Inc.2022Mark Enyedy759,490—4,137,596515,2135,422,421
24MoonLake Immunotherapeutics2025Jorge Santos da Silva762,3864,000,021004,943,209
25Denali Therapeutics Inc.2025Ryan Watts718,0001,151,8672,180,00304,751,515
—Ascendis Pharma, Inc.——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Roivant Sciences Ltd.94.5%not disclosedNoAon
ACADIA Pharmaceuticals Inc.110%Options 50 · PSU 25 · RSU 25YesFrederic W. Cook & Co., Inc. (FW Cook)
Amicus Therapeutics, Inc.not disclosedOption 33 · RSU 33 · PRSU 33Yes — TSR GoalPay Governance
Apellis Pharmaceuticals, Inc.90.74%RSU 50 · PSU 50not disclosedPay Governance
Arcutis Biotherapeutics, Inc.125%not disclosedNoPay Governance LLC
Ascendis Pharma, Inc.not disclosednot disclosednot disclosednot disclosed
Axsome Therapeutics, Inc.150%RSU 33 · Options 33 · PSU 33NoFrederic W. Cook & Co., Inc.
Blueprint Medicines Corporation130%RSU 37 · Options 32 · PSU 31Yes — Relative Total Stockholder Return (rTSR)Aon
BridgeBio Pharma, Inc.135%RSU 50 · PSU 35 · Options 15NoAon Talent Solutions
Cerevel Therapeutics Holdings, Inc.128.8%Options 100not disclosedPay Governance LLC
CRISPR Therapeutics, Inc.not disclosednot disclosednot disclosedAlpine Rewards, LLC
Denali Therapeutics Inc.145%not disclosednot disclosedAlpine Rewards
Exelixis, Inc.105%PSU 50 · RSU 50Yes — 2025 Relative TSR GoalAon
Halozyme Therapeutics, Inc.127.5%PSU 50 · RSU 35 · Option 15NoF.W. Cook & Co., Inc.
ImmunoGen, Inc.not disclosednot disclosednot disclosedAon
Incyte Corporation138.6%Performance Shares 60 · RSU 40Yes — relative total shareholder return (TSR)Aon
Intra-Cellular Therapies, Inc.not disclosedRSU 75 · PRSU 25Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology IndexAon Consulting, Inc.
Ionis Pharmaceuticals, Inc.not disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Jazz Pharmaceuticals, Inc.150%PSU 50 · RSU 50Yes — Relative TSRAon
Karuna Therapeutics, Inc.145%Option 100not disclosedAon
MoonLake Immunotherapeuticsnot disclosednot disclosednot disclosedDeloitte
Neurocrine Biosciences Inc.105%Options 50 · PSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
Revolution Medicines, Inc.146%Options 70 · RSU 30not disclosedCompensia
Sarepta Therapeutics, Inc.100%PSU 50 · Option 25 · RSU 25NoFW Cook
United Therapeutics Corporation221%PSO 50 · PSU 50NoAon
Vaxcyte, Inc.105%not disclosednot disclosedPay Governance

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Roivant Sciences Ltd. in fiscal 2024?
As disclosed, Mayukh Sukhatme (President and Chief Investment Officer) was the highest-paid executive at Roivant Sciences Ltd. in fiscal 2024, with total compensation of $251,858,764.
How does Roivant Sciences Ltd.'s chief executive pay compare to its disclosed peer group?
As disclosed, Matthew Gline's total compensation ranked at the 99th percentile of Roivant Sciences Ltd.'s disclosed peer group.
What is Roivant Sciences Ltd.'s CEO-to-median employee pay ratio?
As disclosed, Roivant Sciences Ltd.'s CEO-to-median employee pay ratio was 518:1.
How did shareholders vote on Roivant Sciences Ltd.'s executive compensation?
As disclosed, 60.91% of shareholders supported Roivant Sciences Ltd.'s executive compensation in the latest say-on-pay vote.
How much does Roivant Sciences Ltd. spend in total on board compensation for fiscal 2024?
As disclosed, Roivant Sciences Ltd. reported total board compensation of $1,642,255 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Mayukh SukhatmeDEF 14A2025-07-290001140361-25-027846Section “Summary Compensation Table”. As printed: 251,858,764. Filing ↗machine: r7 · c24 · span 771923–771935
2Section 01, Matthew GlineDEF 14A2025-07-290001140361-25-027846Section “Summary Compensation Table”. As printed: 163,293,744. Filing ↗machine: r2 · c24 · span 751211–751223
3Section 01, Eric VenkerDEF 14A2025-07-290001140361-25-027846Section “Summary Compensation Table”. As printed: 11,807,422. Filing ↗machine: r10 · c24 · span 784327–784338
4Section 01, Rakhi KumarDEF 14A2025-07-290001140361-25-027846Section “Summary Compensation Table”. As printed: 4,693,938. Filing ↗machine: r14 · c24 · span 800174–800184
5Section 01, Richard PulikDEF 14A2025-07-290001140361-25-027846Section “Summary Compensation Table”. As printed: 4,127,151. Filing ↗machine: r5 · c24 · span 763609–763619
6Section 01, Jennifer HumesDEF 14A2025-07-290001140361-25-027846Section “Summary Compensation Table”. As printed: 2,382,956. Filing ↗machine: r13 · c24 · span 795986–795996
7Section 03, Mayukh Sukhatme RSUDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 874340–874350
8Section 03, Jennifer Humes RSUDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
9Section 03, Rakhi Kumar OPTIONDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
10Section 03, Richard Pulik OPTIONDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
11Section 03, Jennifer Humes OPTIONDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
12Section 03, Eric Venker OPTIONDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
13Section 03, Rakhi Kumar RSUDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
14Section 03, Richard Pulik RSUDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
15Section 03, Matthew Gline RSUDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 852094–852104
16Section 03, Eric Venker RSUDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗
17Section 03, Matthew Gline PSUDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 846486–846498
18Section 03, Mayukh Sukhatme PSUDEF 14A1900-01-010001140361-25-027846Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 868732–868744
19Section 07, pay ratioDEF 14A2025-07-290001140361-25-027846Section “CEO Pay Ratio”. As printed: 518 : 1. Filing ↗
20Section 08, Ilan OrenDEF 14A2025-07-290001140361-25-027846Section “Director Compensation”. As printed: 521,548. Filing ↗machine: t63 · r4 · c15 · span 252945–253128
21Section 08, Melissa EpperlyDEF 14A2025-07-290001140361-25-027846Section “Director Compensation”. As printed: 489,410. Filing ↗machine: t63 · r6 · c15 · span 258817–259000
22Section 08, Daniel GoldDEF 14A2025-07-290001140361-25-027846Section “Director Compensation”. As printed: 484,410. Filing ↗machine: t63 · r2 · c15 · span 247117–247300
23Section 08, Meghan FitzGeraldDEF 14A2025-07-290001140361-25-027846Section “Director Compensation”. As printed: 482,910. Filing ↗machine: t63 · r7 · c15 · span 261396–261578
24Section 08, Keith ManchesterDEF 14A2025-07-290001140361-25-027846Section “Director Compensation”. As printed: 476,660. Filing ↗machine: t63 · r3 · c15 · span 249838–250021
25Section 08, James C. MomtazeeDEF 14A2025-07-290001140361-25-027846Section “Director Compensation”. As printed: 473,844. Filing ↗machine: t63 · r5 · c15 · span 255664–255847
26Section 08, Matthew GlineDEF 14A2025-07-290001140361-25-027846Section “Director Compensation”. As printed: 0. Filing ↗
27Section 08, Mayukh SukhatmeDEF 14A2025-07-290001140361-25-027846Section “Director Compensation”. As printed: 0. Filing ↗
28Section 02, Richard Pulik 2025-12-23Form 42025-12-290001140361-25-046787Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Richard Pulik 2025-12-23Form 42025-12-290001140361-25-046787Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Frank Torti 2025-12-23Form 42025-12-290001140361-25-046788Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Frank Torti 2025-12-24Form 42025-12-290001140361-25-046788Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Eric Venker 2025-12-24Form 42025-12-290001140361-25-046786Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Eric Venker 2025-12-24Form 42025-12-290001140361-25-046786Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Eric Venker 2025-12-24Form 42025-12-290001140361-25-046786Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Frank Torti 2025-12-24Form 42025-12-290001140361-25-046788Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Mayukh Sukhatme 2025-12-29Form 42025-12-310001140361-25-047122Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Mayukh Sukhatme 2025-12-29Form 42025-12-310001140361-25-047122Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Mayukh Sukhatme 2025-12-29Form 42025-12-310001140361-25-047122Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Mayukh Sukhatme 2025-12-29Form 42025-12-310001140361-25-047122Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Mayukh Sukhatme 2025-12-31Form 42025-12-310001140361-25-047122Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Mayukh Sukhatme 2025-12-31Form 42025-12-310001140361-25-047122Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Mayukh Sukhatme 2025-12-31Form 42025-12-310001140361-25-047122Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Mayukh Sukhatme 2025-12-31Form 42025-12-310001140361-25-047122Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Eric Venker 2026-01-12Form 42026-01-140001140361-26-001239Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Eric Venker 2026-01-12Form 42026-01-140001140361-26-001239Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Eric Venker 2026-01-12Form 42026-01-140001140361-26-001239Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Epperly Melissa B, 2026-01-20Form 42026-01-220001140361-26-002085Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Ilan Oren 2026-01-20Form 42026-01-220001140361-26-002086Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, James C. Momtazee 2026-01-20Form 42026-01-220001140361-26-002087Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Epperly Melissa B, 2026-01-20Form 42026-01-220001140361-26-002085Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Ilan Oren 2026-01-20Form 42026-01-220001140361-26-002086Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, James C. Momtazee 2026-01-20Form 42026-01-220001140361-26-002087Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Mayukh Sukhatme 2026-02-09Form 42026-02-110001635088-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Mayukh Sukhatme 2026-02-09Form 42026-02-110001635088-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Mayukh Sukhatme 2026-02-09Form 42026-02-110001635088-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Mayukh Sukhatme 2026-02-09Form 42026-02-110001635088-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, QVT Financial LP 2026-02-11Form 42026-02-130001193125-26-052106Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Daniel Gold 2026-02-11Form 42026-02-130001193125-26-052128Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Keith Manchester 2026-02-11Form 42026-02-130001193125-26-052130Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Daniel Gold 2026-02-12Form 42026-02-130001193125-26-052128Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Daniel Gold 2026-02-12Form 42026-02-130001193125-26-052128Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Keith Manchester 2026-02-12Form 42026-02-130001193125-26-052130Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Keith Manchester 2026-02-12Form 42026-02-130001193125-26-052130Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, QVT Financial LP 2026-02-12Form 42026-02-130001193125-26-052106Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, QVT Financial LP 2026-02-12Form 42026-02-130001193125-26-052106Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, QVT Financial LP 2026-02-13Form 42026-02-130001193125-26-052106Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Daniel Gold 2026-02-13Form 42026-02-130001193125-26-052128Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Keith Manchester 2026-02-13Form 42026-02-130001193125-26-052130Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Eric Venker 2026-02-13Form 42026-02-180001635088-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Eric Venker 2026-02-13Form 42026-02-180001635088-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Eric Venker 2026-02-13Form 42026-02-180001635088-26-000017Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, QVT Financial LP 2026-02-13Form 42026-02-130001193125-26-052106Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Daniel Gold 2026-02-13Form 42026-02-130001193125-26-052128Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Keith Manchester 2026-02-13Form 42026-02-130001193125-26-052130Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Frank Torti 2026-02-19Form 42026-02-230001635088-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Frank Torti 2026-02-19Form 42026-02-230001635088-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Frank Torti 2026-02-19Form 42026-02-230001635088-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Frank Torti 2026-02-20Form 42026-02-230001635088-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Frank Torti 2026-02-20Form 42026-02-230001635088-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Frank Torti 2026-02-20Form 42026-02-230001635088-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Richard Pulik 2026-02-20Form 42026-02-240001635088-26-000023Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Eric Venker 2026-02-20Form 42026-02-240001635088-26-000022Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Frank Torti 2026-02-23Form 42026-02-230001635088-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Frank Torti 2026-02-23Form 42026-02-230001635088-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Frank Torti 2026-02-23Form 42026-02-230001635088-26-000019Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Epperly Melissa B, 2026-03-16Form 42026-03-180001807359-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Eric Venker 2026-03-17Form 42026-03-190001635088-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Eric Venker 2026-03-17Form 42026-03-190001635088-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Eric Venker 2026-03-17Form 42026-03-190001635088-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Jennifer Humes 2026-03-20Form 42026-03-240001635088-26-000029Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, Richard Pulik 2026-03-20Form 42026-03-240001635088-26-000030Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, Meghan FitzGerald 2026-03-26Form 42026-03-300001140361-26-012063Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, Meghan FitzGerald 2026-03-26Form 42026-03-300001140361-26-012063Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, Meghan FitzGerald 2026-03-26Form 42026-03-300001140361-26-012063Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Matthew Gline 2026-03-30Form 42026-04-010001635088-26-000034Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Matthew Gline 2026-03-30Form 42026-04-010001635088-26-000034Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Mayukh Sukhatme 2026-03-30Form 42026-04-010001635088-26-000033Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Matthew Gline 2026-03-30Form 42026-04-010001635088-26-000034Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Mayukh Sukhatme 2026-03-30Form 42026-04-010001635088-26-000033Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Mayukh Sukhatme 2026-03-30Form 42026-04-010001635088-26-000033Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Mayukh Sukhatme 2026-03-31Form 42026-04-010001635088-26-000033Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Matthew Gline 2026-03-31Form 42026-04-010001635088-26-000034Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, Frank Torti 2026-03-31Form 42026-04-020001635088-26-000036Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, Jennifer Humes 2026-04-08Form 42026-04-100001140361-26-014301Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, Matthew Gline 2026-04-16Form 42026-04-200001635088-26-000038Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, Ilan Oren 2026-04-17Form 42026-04-210001140361-26-015985Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, James C. Momtazee 2026-04-17Form 42026-04-210001209181-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, James C. Momtazee 2026-04-17Form 42026-04-210001209181-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, Ilan Oren 2026-04-17Form 42026-04-210001140361-26-015985Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, Epperly Melissa B, 2026-04-17Form 42026-04-210001807359-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, Richard Pulik 2026-04-20Form 42026-04-220001635088-26-000043Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, Jennifer Humes 2026-04-20Form 42026-04-220001635088-26-000042Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, Eric Venker 2026-04-20Form 42026-04-220001635088-26-000044Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, Eric Venker 2026-04-20Form 42026-04-220001635088-26-000044Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, Eric Venker 2026-04-20Form 42026-04-220001635088-26-000044Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, Jennifer Humes 2026-04-20Form 42026-04-220001635088-26-000042Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, Richard Pulik 2026-04-20Form 42026-04-220001635088-26-000043Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, Eric Venker 2026-05-20Form 42026-05-220001635088-26-000065Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, Richard Pulik 2026-05-20Form 42026-05-220001635088-26-000064Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, Eric Venker 2026-05-22Form 42026-05-220001635088-26-000065Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, Eric Venker 2026-05-22Form 42026-05-220001635088-26-000065Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, Eric Venker 2026-05-22Form 42026-05-220001635088-26-000065Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, Richard Pulik 2026-06-20Form 42026-06-230001635088-26-000069Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, Jennifer Humes 2026-06-20Form 42026-06-230001635088-26-000067Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Eric Venker 2026-06-24Form 42026-06-260001635088-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Eric Venker 2026-06-24Form 42026-06-260001635088-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Eric Venker 2026-06-24Form 42026-06-260001635088-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Eric Venker 2026-06-24Form 42026-06-260001635088-26-000071Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Mayukh Sukhatme 2026-06-25Form 42026-06-290001635088-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Mayukh Sukhatme 2026-06-25Form 42026-06-290001635088-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Mayukh Sukhatme 2026-06-25Form 42026-06-290001635088-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, Mayukh Sukhatme 2026-06-26Form 42026-06-290001635088-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Daniel Gold 2026-06-26Form 42026-06-300001193125-26-291163Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, QVT Financial LP 2026-06-26Form 42026-06-300001193125-26-291139Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, QVT Financial LP 2026-06-26Form 42026-06-300001193125-26-291139Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, Keith Manchester 2026-06-26Form 42026-06-300001193125-26-291172Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, Mayukh Sukhatme 2026-06-26Form 42026-06-290001635088-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, Mayukh Sukhatme 2026-06-26Form 42026-06-290001635088-26-000073Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, Daniel Gold 2026-06-26Form 42026-06-300001193125-26-291163Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Keith Manchester 2026-06-26Form 42026-06-300001193125-26-291172Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, QVT Financial LP 2026-06-29Form 42026-06-300001193125-26-291139Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Keith Manchester 2026-06-29Form 42026-06-300001193125-26-291172Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, Epperly Melissa B, 2026-06-29Form 42026-07-010001807359-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, Epperly Melissa B, 2026-06-29Form 42026-07-010001807359-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, Epperly Melissa B, 2026-06-29Form 42026-07-010001807359-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, Daniel Gold 2026-06-29Form 42026-06-300001193125-26-291163Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, Daniel Gold 2026-06-29Form 42026-06-300001193125-26-291163Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, QVT Financial LP 2026-06-29Form 42026-06-300001193125-26-291139Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Keith Manchester 2026-06-29Form 42026-06-300001193125-26-291172Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Epperly Melissa B, 2026-06-29Form 42026-07-010001807359-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, QVT Financial LP 2026-06-30Form 42026-06-300001193125-26-291139Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Meghan FitzGerald 2026-06-30Form 42026-07-020001349297-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Matthew Gline 2026-06-30Form 42026-07-020001635088-26-000079Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Keith Manchester 2026-06-30Form 42026-06-300001193125-26-291172Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Mayukh Sukhatme 2026-06-30Form 42026-07-020001635088-26-000075Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Keith Manchester 2026-06-30Form 42026-06-300001193125-26-291172Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Frank Torti 2026-06-30Form 42026-07-020001635088-26-000077Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Meghan FitzGerald 2026-06-30Form 42026-07-020001349297-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Meghan FitzGerald 2026-06-30Form 42026-07-020001349297-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Daniel Gold 2026-06-30Form 42026-06-300001193125-26-291163Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Ilan Oren 2026-07-17Form 42026-07-210001140361-26-029191Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, James C. Momtazee 2026-07-17Form 42026-07-210001140361-26-029193Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Epperly Melissa B, 2026-07-17Form 42026-07-210001140361-26-029192Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Eric Venker 2026-07-27Form 42026-07-290001140361-26-030107Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Eric Venker 2026-07-27Form 42026-07-290001140361-26-030107Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Eric Venker 2026-07-27Form 42026-07-290001140361-26-030107Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Mayukh Sukhatme 2026-08-14Form 42026-08-180001140361-26-033637Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Mayukh Sukhatme 2026-08-14Form 42026-08-180001140361-26-033637Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Mayukh Sukhatme 2026-08-14Form 42026-08-180001140361-26-033637Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Mayukh Sukhatme 2026-08-17Form 42026-08-180001140361-26-033637Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Mayukh Sukhatme 2026-08-17Form 42026-08-180001140361-26-033637Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Mayukh Sukhatme 2026-08-17Form 42026-08-180001140361-26-033637Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Mayukh Sukhatme 2026-08-18Form 42026-08-180001140361-26-033637Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Mayukh Sukhatme 2026-08-18Form 42026-08-180001140361-26-033637Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Mayukh Sukhatme 2026-08-18Form 42026-08-180001140361-26-033637Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Mayukh Sukhatme 2026-08-18Form 42026-08-180001140361-26-033637Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Mayukh Sukhatme 2026-08-18Form 42026-08-180001140361-26-033637Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Mayukh Sukhatme 2026-08-19Form 42026-08-210001140361-26-034066Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, Mayukh Sukhatme 2026-08-19Form 42026-08-210001140361-26-034066Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, Mayukh Sukhatme 2026-08-19Form 42026-08-210001140361-26-034066Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, Eric Venker 2026-08-20Form 42026-08-240001140361-26-034238Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, Mayukh Sukhatme 2026-08-20Form 42026-08-210001140361-26-034066Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Mayukh Sukhatme 2026-08-20Form 42026-08-210001140361-26-034066Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Mayukh Sukhatme 2026-08-20Form 42026-08-210001140361-26-034066Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, Mayukh Sukhatme 2026-08-21Form 42026-08-210001140361-26-034066Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, Mayukh Sukhatme 2026-08-21Form 42026-08-210001140361-26-034066Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, Mayukh Sukhatme 2026-08-21Form 42026-08-210001140361-26-034066Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, Eric Venker 2026-08-28Form 42026-09-010001140361-26-035375Insider equity transaction reported since the proxy statement. Filing ↗
189Section 02, Eric Venker 2026-08-28Form 42026-09-010001140361-26-035375Insider equity transaction reported since the proxy statement. Filing ↗
190Section 02, Eric Venker 2026-08-28Form 42026-09-010001140361-26-035375Insider equity transaction reported since the proxy statement. Filing ↗
191Section 02, Eric Venker 2026-08-28Form 42026-09-010001140361-26-035375Insider equity transaction reported since the proxy statement. Filing ↗
192Section 02, Meghan FitzGerald 2026-09-08Form 42026-09-100001140361-26-036246Insider equity transaction reported since the proxy statement. Filing ↗
193Section 02, Meghan FitzGerald 2026-09-08Form 42026-09-100001140361-26-036246Insider equity transaction reported since the proxy statement. Filing ↗
194Section 02, Meghan FitzGerald 2026-09-08Form 42026-09-100001140361-26-036246Insider equity transaction reported since the proxy statement. Filing ↗
195Section 02, Epperly Melissa B, 2026-09-10Form 42026-09-140001807359-26-000012Insider equity transaction reported since the proxy statement. Filing ↗
196Section 02, James C. Momtazee 2026-09-10Form 42026-09-140001209181-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
197Section 02, Meghan FitzGerald 2026-09-10Form 42026-09-140001349297-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
198Section 02, Daniel Gold 2026-09-10Form 42026-09-140001140361-26-036535Insider equity transaction reported since the proxy statement. Filing ↗
199Section 02, Ilan Oren 2026-09-10Form 42026-09-140001635088-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
200Section 02, Epperly Melissa B, 2026-09-15Form 42026-09-170001807359-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
201Section 02, Meghan FitzGerald 2026-09-15Form 42026-09-170001349297-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
202Section 02, Epperly Melissa B, 2026-09-15Form 42026-09-170001807359-26-000014Insider equity transaction reported since the proxy statement. Filing ↗
203Section 02, Meghan FitzGerald 2026-09-15Form 42026-09-170001349297-26-000008Insider equity transaction reported since the proxy statement. Filing ↗
204Section 02, Epperly Melissa B, 2026-09-16Form 42026-09-180001807359-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
205Section 02, James C. Momtazee 2026-09-16Form 42026-09-180001209181-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
206Section 02, James C. Momtazee 2026-09-16Form 42026-09-180001209181-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
207Section 02, Ilan Oren 2026-09-16Form 42026-09-180001635088-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
208Section 02, Daniel Gold 2026-09-16Form 42026-09-180001635088-26-000102Insider equity transaction reported since the proxy statement. Filing ↗
209Section 02, Daniel Gold 2026-09-16Form 42026-09-180001635088-26-000102Insider equity transaction reported since the proxy statement. Filing ↗
210Section 02, Keith Manchester 2026-09-16Form 42026-09-180001140361-26-037158Insider equity transaction reported since the proxy statement. Filing ↗
211Section 02, Keith Manchester 2026-09-16Form 42026-09-180001140361-26-037158Insider equity transaction reported since the proxy statement. Filing ↗
212Section 02, Epperly Melissa B, 2026-09-16Form 42026-09-180001807359-26-000016Insider equity transaction reported since the proxy statement. Filing ↗
213Section 02, Ilan Oren 2026-09-16Form 42026-09-180001635088-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
214Section 02, Meghan FitzGerald 2026-09-16Form 42026-09-180001349297-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
215Section 02, Meghan FitzGerald 2026-09-16Form 42026-09-180001349297-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
216Section 02, Richard Pulik 2026-09-20Form 42026-09-220001635088-26-000104Insider equity transaction reported since the proxy statement. Filing ↗
217Section 02, Jennifer Humes 2026-09-20Form 42026-09-220001140361-26-037363Insider equity transaction reported since the proxy statement. Filing ↗
218Section 02, Eric Venker 2026-09-30Form 42026-10-020001635088-26-000108Insider equity transaction reported since the proxy statement. Filing ↗
219Section 02, Eric Venker 2026-09-30Form 42026-10-020001635088-26-000108Insider equity transaction reported since the proxy statement. Filing ↗
220Section 02, Eric Venker 2026-09-30Form 42026-10-020001635088-26-000108Insider equity transaction reported since the proxy statement. Filing ↗
221Section 02, Mayukh Sukhatme 2026-09-30Form 42026-10-020001635088-26-000109Insider equity transaction reported since the proxy statement. Filing ↗
222Section 02, Matthew Gline 2026-09-30Form 42026-10-020001140361-26-038475Insider equity transaction reported since the proxy statement. Filing ↗
223Section 02, Frank Torti 2026-09-30Form 42026-10-020001140361-26-038474Insider equity transaction reported since the proxy statement. Filing ↗
224Section 02, Epperly Melissa B, 2026-10-01Form 42026-10-050001807359-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
225Section 02, Epperly Melissa B, 2026-10-01Form 42026-10-050001807359-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
226Section 02, Epperly Melissa B, 2026-10-01Form 42026-10-050001807359-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
227Section 02, Epperly Melissa B, 2026-10-01Form 42026-10-050001807359-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
228Section 06, 2025 voteForm 8-K2025-09-110001140361-25-034711Item 5.07 · say-on-pay result. As reported: 60.91% (votes for as printed: 316,651,402). Filing ↗
229Section 06, 2024 voteForm 8-K2024-09-160001140361-24-041188Item 5.07 · say-on-pay result. As reported: 89.34% (votes for as printed: 540,184,951). Filing ↗
230Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
231Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
232Section 09b board cost (computed)Computed——Cash 442,321 + equity 1,199,934 + all other 0 = 1,642,255, summed across the director compensation table rows.machine: formula: Σ = 1,642,255
233Roivant Sciences Ltd. (subject), Section 10b CEO totalDEF 14A2025-07-290001140361-25-027846CEO total compensation as printed in Roivant Sciences Ltd.'s own proxy. As printed: 163,293,744. Filing ↗machine: r2 · c24 · span 751211–751223
234Exelixis, Inc., Section 10b CEO totalDEF 14A2026-04-150000939767-26-000046CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526
235Incyte Corporation, Section 10b CEO totalDEF 14A2026-04-280000879169-26-000031CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827
236Halozyme Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-03-230001159036-26-000041CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292
237Jazz Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-06-080001232524-26-000029CEO total compensation as printed in Jazz Pharmaceuticals, Inc.'s own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379
238United Therapeutics Corporation, Section 10b CEO totalDEF 14A2026-04-290001082554-26-000009CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736
239BridgeBio Pharma, Inc., Section 10b CEO totalDEF 14A2026-04-240001140361-26-016723CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531
240Revolution Medicines, Inc., Section 10b CEO totalDEF 14A2026-04-270001193125-26-182453CEO total compensation as printed in Revolution Medicines, Inc.'s own proxy. As printed: 14,672,390. Filing ↗machine: r2 · c27 · span 382608–382618
241Vaxcyte, Inc., Section 10b CEO totalDEF 14A2026-04-230001193125-26-173672CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. Filing ↗machine: r2 · c30 · span 561197–561207
242Blueprint Medicines Corporation, Section 10b CEO totalDEF 14A2025-04-240001558370-25-005415CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162
243Neurocrine Biosciences Inc., Section 10b CEO totalDEF 14A2026-04-150000914475-26-000015CEO total compensation as printed in Neurocrine Biosciences Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957
244Ionis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2026-04-230001140361-26-016388CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗
245Cerevel Therapeutics Holdings, Inc., Section 10b CEO totalDEF 14A2023-04-280000950170-23-015766CEO total compensation as printed in Cerevel Therapeutics Holdings, Inc.'s own proxy. As printed: 11,225,426. Filing ↗machine: t23 · r2 · c29 · span 1010006–1010016
246Karuna Therapeutics, Inc., Section 10b CEO totalDEF 14A2023-04-270000950170-23-014979CEO total compensation as printed in Karuna Therapeutics, Inc.'s own proxy. As printed: 11,224,103. Filing ↗machine: r2 · c25 · span 856684–856694
247Apellis Pharmaceuticals, Inc., Section 10b CEO totalDEF 14A2025-04-230000950170-25-056966CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565
248Axsome Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177610CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246
249Intra-Cellular Therapies, Inc., Section 10b CEO totalDEF 14A2024-04-290001628280-24-018986CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603
250Amicus Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-240001140361-25-015479CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136
251ACADIA Pharmaceuticals Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-174163CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗
252Sarepta Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-240001193125-26-177247CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404
253CRISPR Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-210001193125-26-165158CEO total compensation as printed in CRISPR Therapeutics, Inc.'s own proxy. As printed: 7,678,477. Filing ↗machine: r2 · c25 · span 821649–821658
254Arcutis Biotherapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-210001787306-26-000028CEO total compensation as printed in Arcutis Biotherapeutics, Inc.'s own proxy. As printed: 7,223,065. Filing ↗machine: r2 · c42 · span 646815–646824
255ImmunoGen, Inc., Section 10b CEO totalDEF 14A2023-04-260001558370-23-006874CEO total compensation as printed in ImmunoGen, Inc.'s own proxy. As printed: 5,422,421. Filing ↗
256MoonLake Immunotherapeutics, Section 10b CEO totalDEF 14A2026-04-210001140361-26-015916CEO total compensation as printed in MoonLake Immunotherapeutics's own proxy. As printed: 4,943,209. Filing ↗machine: t83 · r2 · c24 · span 431198–431207
257Denali Therapeutics Inc., Section 10b CEO totalDEF 14A2026-04-210001714899-26-000054CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614
258Section 10a, Jazz Pharmaceuticals, Inc. reciprocityDEF 14A—0001232524-26-000029Jazz Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
259Section 10a, Amicus Therapeutics, Inc. reciprocityDEF 14A—0001140361-25-015479Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
260Section 10a, MoonLake Immunotherapeutics reciprocityDEF 14A—0001140361-26-015916MoonLake Immunotherapeutics's most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
261Section 10a, Exelixis, Inc. reciprocityDEF 14A—0000939767-26-000046Exelixis, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
262Section 10a, Neurocrine Biosciences Inc. reciprocityDEF 14A—0000914475-26-000015Neurocrine Biosciences Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
263Section 10a, Revolution Medicines, Inc. reciprocityDEF 14A—0001193125-26-182453Revolution Medicines, Inc. names Roivant Sciences Ltd. in its own disclosed peer group (read from its most recent proxy). Filing ↗
264Section 10a, Sarepta Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-177247Sarepta Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
265Section 10a, United Therapeutics Corporation reciprocityDEF 14A—0001082554-26-000009United Therapeutics Corporation's most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
266Section 10a, Ionis Pharmaceuticals, Inc. reciprocityDEF 14A—0001140361-26-016388Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
267Section 10a, ACADIA Pharmaceuticals Inc. reciprocityDEF 14A—0001193125-26-174163ACADIA Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
268Section 10a, CRISPR Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-165158CRISPR Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
269Section 10a, Denali Therapeutics Inc. reciprocityDEF 14A—0001714899-26-000054Denali Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
270Section 10a, Apellis Pharmaceuticals, Inc. reciprocityDEF 14A—0000950170-25-056966Apellis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
271Section 10a, Arcutis Biotherapeutics, Inc. reciprocityDEF 14A—0001787306-26-000028Arcutis Biotherapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
272Section 10a, Halozyme Therapeutics, Inc. reciprocityDEF 14A—0001159036-26-000041Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
273Section 10a, Axsome Therapeutics, Inc. reciprocityDEF 14A—0001193125-26-177610Axsome Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
274Section 10a, Blueprint Medicines Corporation reciprocityDEF 14A—0001558370-25-005415Blueprint Medicines Corporation's most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
275Section 10a, Vaxcyte, Inc. reciprocityDEF 14A—0001193125-26-173672Vaxcyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
276Section 10a, BridgeBio Pharma, Inc. reciprocityDEF 14A—0001140361-26-016723BridgeBio Pharma, Inc. names Roivant Sciences Ltd. in its own disclosed peer group (read from its most recent proxy). Filing ↗
277Section 10a, Intra-Cellular Therapies, Inc. reciprocityDEF 14A—0001628280-24-018986Intra-Cellular Therapies, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
278Section 10a, Karuna Therapeutics, Inc. reciprocityDEF 14A—0000950170-23-014979Karuna Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
279Section 10a, Cerevel Therapeutics Holdings, Inc. reciprocityDEF 14A—0000950170-23-015766Cerevel Therapeutics Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗
280Section 10a, ImmunoGen, Inc. reciprocityDEF 14A—0001558370-23-006874ImmunoGen, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

Get the Roivant Sciences Ltd. Executive Compensation Report

$1,500

Buy the report - $1,500Both reports - $2,400
ROIV Peer Teardown Report